Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib combined with S-1 for advanced non-small cell lung cancer
ChiCTR1900020948Phase 4Recruiting
- Sponsor
- Mianyang Central Hospital
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib and tegafur in non-small cell lung cancer (NSCLC), sponsored by Mianyang Central Hospital. Primary endpoints: Complete response rate and Partial response rate. Started Jan 2019; status: recruiting.
02
Drugs
anlotinibtegafur
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900020948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020948.